TherapeuticsMD, Inc.
TXMD
$2.02
-$0.18-8.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.88% | 43.33% | 306.84% | 25.56% | 32.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.88% | 43.33% | 306.84% | 25.56% | 32.87% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 33.88% | 43.33% | 306.84% | 25.56% | 32.87% |
| SG&A Expenses | 100.80% | -24.89% | -4.70% | -18.23% | -40.45% |
| Depreciation & Amortization | -3.00% | 0.00% | -46.67% | -28.57% | -84.30% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.19% | -23.19% | -10.05% | -19.18% | -53.67% |
| Operating Income | -210.58% | 65.54% | 72.94% | 31.44% | 80.63% |
| Income Before Tax | -798.80% | 108.82% | 151.90% | 17.43% | 105.24% |
| Income Tax Expenses | 203.23% | -- | -- | -- | 27.91% |
| Earnings from Continuing Operations | -636.84% | 108.82% | 151.90% | 21.38% | 107.40% |
| Earnings from Discontinued Operations | -105.07% | 342.86% | 115.00% | -122.67% | -79.03% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -345.63% | 124.96% | 150.55% | 11.04% | 128.54% |
| EBIT | -210.58% | 65.54% | 72.94% | 31.44% | 80.63% |
| EBITDA | -311.32% | 73.79% | 77.68% | 31.81% | 85.45% |
| EPS Basic | -344.29% | 124.81% | 150.37% | 11.16% | 127.38% |
| Normalized Basic EPS | -677.55% | 114.33% | 157.89% | 28.31% | 105.46% |
| EPS Diluted | -360.27% | 118.66% | 150.37% | 3.30% | 126.16% |
| Normalized Diluted EPS | -677.55% | 114.33% | 157.89% | 28.31% | 105.46% |
| Average Basic Shares Outstanding | 0.37% | 0.36% | 0.36% | 0.17% | 4.45% |
| Average Diluted Shares Outstanding | 0.37% | 0.36% | 0.36% | 0.17% | 4.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |